Breathing easy: dynamic x-rays may spot COPD faster and safer
NCT ID NCT06653413
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests whether a special type of chest X-ray, called dynamic chest radiography, can help diagnose chronic obstructive pulmonary disease (COPD). Currently, COPD is diagnosed with lung function tests that require strong patient effort and may not be possible during a respiratory pandemic. The study will measure diaphragm movement and lung area changes on X-rays from 2,500 people with COPD and compare them to standard lung function results. If the X-ray method proves reliable, it could offer a faster, lower-risk way to diagnose COPD.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, dynamic chest X-rays could become a quicker, more accessible way to diagnose COPD, especially during respiratory pandemics when standard tests are risky.
- What could go wrong
- This is an early diagnostic study, not a treatment trial. The technique may not prove accurate enough to replace standard lung function tests, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This is a prospective clinical study of COPD patients and normal subjects in our hospital. This study has been approved by the hospital Ethics Committee and the patient's informed consent has been obtained (approval number: MR-44-24-016286).
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- COPD group: (1) Patients ≥30 years of age and ≤ 80 years of age who meet the 2023 GOLD Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease, i.e., anyone who complains of dyspnea, chronic cough or sputum, a history of recurrent lower respiratory infection and/or exposure to disease risk factors, Moreover, pulmonary function examination indicated that FEV1/FVC \<0.7 after bronchodilator was used to confirm COPD. FEV1%pred is used to determine the severity of airflow obstruction: Grade GOLD 1 (mild) : FEV1%pred ≥ 80%, Grade GOLD2 (moderate) : 50% ≤ FEV1%pred \< 80%, grade GOLD3 (severe) : 30% ≤ FEV1%pred \< 50%, GOLD4 grade (extremely severe) : FEV1%pred \< 30%; (2) Signing informed consent; (3) Can cooperate with the completion of dynamic chest X-ray (complete dynamic chest X-ray positioning for 20 seconds, during which calm breathing, hard breathing, can hold breath for at least 7 seconds). Normal Group: (1) Age ≥30 years old and ≤ 80 years old; (2) Normal pulmonary ventilation function; (3) Exclude chronic airway diseases (such as COPD, asthma, bronchiectasis, etc.); (4) Signing informed consent; (5) Can cooperate with the completion of dynamic chest X-ray (complete dynamic chest X-ray positioning for 20 seconds, during which calm breathing, hard breathing, can hold breath for at least 7 seconds). Exclusion Criteria: * COPD group: (1) A history of cancer, lung surgery, other lung diseases (such as pneumonia, active tuberculosis, severe bronchiectasis); (2) Combined with muscle-related diseases such as myasthenia gravis or wasting diseases that affect muscle mass such as severe hyperthyroidism and advanced malignant diseases; (3) Pregnant or lactating women; (4) Significant radiation exposure (dose \>10mSv) was involved in the 12 months prior to study participation. Normal Group: (1) Have acute or chronic cardiopulmonary disease in the past, abnormal lung physical examination and lung imaging examination in the past, and have a history of infectious diseases within the past 1 month; (2) Pregnant or lactating women; (3) Significant radiation exposure (dose \>10mSv) was involved in the 12 months prior to study participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Guangdong Locations
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new inhaler match Symbicort's performance?
- Gentler exercise with a twist: could a tourniquet boost balance in lung disease?
- Personalized exercise plans could boost COPD recovery
- Can a nasal oxygen device prevent dangerous dips in blood oxygen during endoscopy for COPD patients?
- Drones may rush donor lungs to transplant patients, saving precious time
- Could a simple ultrasound predict ventilator success in elderly COPD patients?